- Trial Phase
- Approved (Accelerated Approval)
- Time to Market
- Already FDA-approved (July 7, 2026) — launched commercially; confirmatory full-approval data expected Q3 2026
- Why 5/10
- TRUTAKNA received accelerated FDA approval on July 7, 2026 — the defining binary event has passed. The next hard catalyst is the ORIGIN 3 confirmatory eGFR data expected in Q3 2026 (within ~3 months), which supports conversion to full approval. ImpactScore is 5 because the drug is already approved and commercializing, but the confirmatory eGFR readout in ~Q3 2026 and potential sBLA filing in Q4 2026 are still meaningful catalysts for a company whose value is almost entirely this one asset.
The FDA approval is already priced in (modest +6.8% move on the day). The real binary catalysts ahead are the ORIGIN 3 eGFR confirmatory data (Q3 2026) and commercial launch execution metrics. Watch pricing/reimbursement decisions, early prescription uptake, and whether the confirmatory eGFR data supports full approval. The IgAN market is getting crowded (Tarpeyo, Filspari, Fabhalta, Vanrafia, Voyxact), so differentiation on convenience (at-home autoinjector) and upstream mechanism (dual BAFF/APRIL) will determine commercial success.
Price Chart
Executive Summary
TRUTAKNA (atacicept-vymj) is Vera Therapeutics' first approved product — a dual BAFF/APRIL inhibitor for IgA nephropathy (IgAN), a chronic autoimmune kidney disease. The FDA granted accelerated approval on July 7, 2026, following positive Phase 3 ORIGIN 3 data showing 46% proteinuria reduction. As the first approved therapy targeting the root immunological cause of IgAN, it competes in a growing market projected to reach ~$730M in 2024 and expand at ~30% CAGR. Vera had ~$715M in cash as of Dec 2025 and can access up to $500M via an Oxford debt facility ($75M drawable on this approval). Analyst consensus is Strong Buy with a mean price target of $78 (~80% upside from ~$43), though the approval event produced only a modest +6.8% stock move, suggesting market expectations were already baked in. Key risks include a crowded competitive landscape (Novartis, Otsuka, Travere, Calliditas), pricing/reimbursement pressures, and the need to confirm eGFR benefits for full approval in Q3 2026.
How It Works
TRUTAKNA is a once-weekly, at-home injectable drug that blocks two immune signaling proteins called BAFF and APRIL. In IgA nephropathy (IgAN), the immune system produces abnormal antibodies that build up in the kidneys' filters, causing damage and eventual kidney failure. By blocking BAFF and APRIL, TRUTAKNA reduces the production of these abnormal antibodies at the source, slowing or stopping kidney damage. This is a disease-modifying approach (targeting root cause) rather than just managing symptoms.
Trial Status
FDA granted accelerated approval on July 7, 2026 based on a prespecified interim analysis of the ongoing Phase 3 ORIGIN 3 trial. The trial showed a statistically significant 46% reduction in proteinuria (UPCR) at 36 weeks vs baseline (42% vs placebo, p<0.0001). The confirmatory eGFR (kidney function) analysis has been accelerated to Q3 2026 (pulled forward from 2027) under an FDA-aligned plan, with a supplemental BLA for full approval targeted for Q4 2026. The ORIGIN 3 trial continues through 104 weeks (data expected 2027). Atacicept has been studied in >1,500 patients across multiple indications.
The Two-Sided Case
Upcoming Catalysts
- ORIGIN 3 confirmatory eGFR (kidney function) data — expected Q3 2026 (pulled forward from 2027 under FDA-aligned plan)
- Supplemental BLA submission for full (traditional) FDA approval — expected Q4 2026
- Commercial launch metrics: early prescription uptake, pricing/reimbursement announcements, payer coverage decisions
- PIONEER Phase 2 trial in multiple autoimmune glomerular diseases (lupus nephritis) — data readout
- Potential additional indications in lupus nephritis (LN) and other autoimmune kidney diseases
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Vera Therapeutics, Inc. 8-K VERA ·Originating report